RSV Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Vaccines Type (Live Attenuated Vaccines, Subunit Vaccines, mRNA-based Vaccines, Vector-based Vaccines, Others), By Route of Administration (Intramuscular, Intranasal, Others), By End User (Hospitals, Clinics, Government Vaccination Programs, Others) and Region 2020-2031

RSV Vaccine Market size was valued at US$ 3,650.2 million in 2024 and is projected to reach US$ 9,828.4 million by 2031 at a CAGR of 15.2% from 2025-2031. Moreover, the U.S. market is projected to grow at 15.0% over the forecast period. The respiratory syncytial virus (RSV) vaccine market refers to the global industry involved in the research, development, production, and distribution of vaccines that protect against RSV infection. RSV is a contagious virus that causes respiratory tract infections, particularly severe in infants, young children, and the elderly, and vaccines are developed to prevent these infections through immunization strategies.

The market is witnessing rapid growth due to the increased prevalence of RSV infections and rising awareness about pediatric and geriatric respiratory health. Recent regulatory approvals of RSV vaccines for both infants and older adults have marked a turning point, driving widespread adoption globally. Pharmaceutical companies are investing heavily in R&D and partnerships to expand vaccine access, especially in high-burden regions.

Facts & Figures

• In fact, Over 33 million cases of RSV-associated acute lower respiratory infections occur globally each year in children under 5 years of age.
• More than 3.6 million hospitalizations and approximately 100,000 deaths are attributed to RSV in children under 5 annually, according to WHO and global health bodies.
• In the United States alone, RSV leads to 177,000 hospitalizations and 14,000 deaths annually among adults aged 65 years and older.
• Pfizer’s Abrysvo and GSK’s Arexvy RSV vaccines were both approved by the U.S. FDA in May 2023, marking the first RSV vaccines for older adults.

Recent Developments

• In March 2025, the World Health Organization (WHO) prequalified Pfizer’s maternal RSV vaccine, Abrysvo, making it eligible for global procurement through organizations like UNICEF and Gavi. This critical milestone allows broader use of the vaccine in low- and middle-income countries, particularly to protect infants through passive immunity transferred during pregnancy.
• In June 2025, the U.S. FDA approved Merck’s RSV monoclonal antibody, marketed as Enflonsia (clesrovimab), for preventing lower respiratory tract infections in infants. The approval followed promising trial results showing up to 90.9% efficacy against severe RSV disease.

RSV Vaccine Market Segmentation

Based on the vaccine type

• Live Attenuated Vaccines
• Subunit Vaccines
• mRNA-based Vaccines
• Vector-based Vaccines
• Others

Among the various vaccine types, subunit vaccines are anticipated to lead the RSV vaccine market due to their strong safety profile and proven immunogenicity. Unlike live attenuated vaccines, subunit vaccines contain only specific proteins of the virus, minimizing the risk of adverse effects especially crucial for vulnerable groups like infants, pregnant women, and the elderly. Their stability, ease of production, and favorable response in clinical trials have driven widespread adoption. Pharmaceutical giants such as GSK and Pfizer have launched subunit-based RSV vaccines with high efficacy rates, reinforcing their market leadership. These vaccines are also more acceptable in regulatory environments, accelerating their global rollout.

Based on the route of administration

• Intramuscular
• Intranasal
• Others

Based on the route of administration, intramuscular vaccines are anticipated to dominate the RSV vaccine market due to their widespread use, established delivery method, and high patient compliance. Intramuscular administration ensures efficient absorption and a strong immune response, making it the preferred choice for adult and pediatric immunizations. Leading RSV vaccines approved for use in older adults and maternal populations such as those by Pfizer and GSK utilize this route, further reinforcing its dominance. Healthcare providers are also well-equipped to administer intramuscular injections, ensuring ease of integration into routine immunization programs. This route’s reliability and scalability make it a leading choice globally.

Based on the end user

• Hospitals
• Clinics
• Government Vaccination Programs
• Others

Based on the end user, government vaccination programs are expected to hold the leading share in the RSV vaccine market due to their large-scale reach, public health focus, and policy-driven immunization initiatives. These programs play a vital role in ensuring vaccine accessibility and affordability, especially in low- and middle-income countries where RSV burden is high. Through centralized procurement and distribution, governments can implement mass vaccination campaigns targeting high-risk groups such as infants, pregnant women, and the elderly. The inclusion of RSV vaccines in national immunization schedules, supported by partnerships with global health organizations like WHO and Gavi, further strengthens this segment’s dominance.